medicine-news-1/life-beyond-cancer-womens-retreat-calls-for-applications-48335-2/;/a><br

Breaking Biology Technology:Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 2 Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products 3 Martek Signs Sole-Source Supply Agreement with Fonterra 2 Martek Signs Sole-Source Supply Agreement with Fonterra 3 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 2 Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors 3 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 2 Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner 3

[0] Vivakor Receives $5 Million Licensing and Purchase Agreement for Nutraceutical Products [0] Martek Signs Sole-Source Supply Agreement with Fonterra [0] Northwest Biotherapeutics Announces Appointment of Robert A. Farmer to the Board of Directors [0] Life Line Screening Joins the Vascular Disease Foundation as Corporate Partner

Breaking Medicine Technology:Boston Scientific Announces Pricing of $2 Billion of Senior Notes 2 Boston Scientific Announces Pricing of $2 Billion of Senior Notes 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4 Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5 Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6 Mesa Labs Increases Quarterly Dividend 61255 1 Neogen to Ring NASDAQs Closing Bell 14815 1 Neogen to Ring NASDAQs Closing Bell 14815 2 Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 1 Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 2 Corgenix Reports Financial Results for First Quarter of Fiscal 2010 6217 3

[0] Boston Scientific Announces Pricing of $2 Billion of Senior Notes [0] Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy [0] Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer